Digital Therapeutics (DTx) Market

Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global Forecasts to 2026

Report Code: HIT 4407 Jul, 2021, by marketsandmarkets.com

[204 Pages Report] The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period. Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics.

Digital Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact on the Digital Therapeutics Market

The impact of the coronavirus pandemic and the subsequent establishment of nationwide lockdowns is visible in various industries. The overall growth of various sectors has been heavily impacted, especially in countries with a high incidence rate of COVID-19, such as India, China, Brazil, the US, and several European countries (including Russia, Italy, and Spain). While industries such as oil and petroleum, aeronautics, and mining are experiencing a steep fall in revenues, the healthcare, biotechnology, and pharmaceutical industries are optimizing this situation to serve a maximum number of patients and healthcare professionals.

As of June 28, 2021, there have been 179,686071 confirmed COVID-19 cases worldwide, with 3,899,172 deaths (WHO). As the pandemic continues to spread, healthcare professionals are being stretched to combat the outbreak, but an ever-increasing number of cases is causing severe complications. As a result, patients are increasingly turning to digital therapeutics for disease evaluation and treatment. The COVID-19 outbreak has also prompted healthcare providers to explore alternatives to standard procedures. The COVID-19 outbreak has prompted healthcare providers to seek out alternatives to standard systems and processes. As a result, both providers and consumers are adopting digital therapeutics increasingly.

Digital therapeutics mARKET dynamics

Drivers: Increasing incidence of preventable chronic diseases

Chronic diseases have increased the burden on healthcare systems across the globe. For example, as per a report—Heart Diseases and Stroke Statistics at a Glance (2016, published by the American Heart Association)—cardiovascular disease (CVD) is the leading cause of death globally. CVD accounts for 17.3 million deaths per year, and this figure is expected to cross 23.6 million by 2030.

The high prevalence and incidence rate of chronic diseases is a major concern for healthcare systems across the globe. The treatment of patients with chronic diseases is a significant challenge, as psychosomatic or biopsychic factors very often influence these patients. As chronic diseases are often associated with high levels of uncertainty, patients need to change their behavior as part of a new self-care lifestyle. Furthermore, many chronic disorders and conditions are progressive, and their incidence increases with age. As a result, with significant growth in the global geriatric population, chronic disorders are expected to rise further in the coming years.

Restraints: Patient data privacy concerns

In many countries, various health apps are deprived of appropriate approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security, and the responsible use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient’s data is at risk of being accessed by any healthcare professional not related to the patient’s treatment program.

Some countries, such as the US (with its Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health (HITECH) Act), have legislation focusing on the issue of data security. However, despite such federal initiatives, digital therapeutics users are subject to infringement and data breaching, which may restrain the growth of the digital therapeutics market.

Opportunities: Emerging markets

Emerging economies such as India, China, and the Middle East present growth opportunities for digital therapeutics. In most geographies, the market is still in its infancy due to a lack of awareness, the minimum availability of these solutions, lack of IT infrastructure, and financial and social constraints. On the other hand, most emerging economies show high rates of chronic disease incidence. According to WHO estimates, by 2020, chronic diseases will be responsible for 70% of the total deaths in developing countries. On the global level, by 2025, ~60% of the burden of chronic conditions will be in developing countries.

In addition, the lack of skilled medical practitioners in developing regions highlights the importance of connected healthcare. Furthermore, developing countries like India and China lack proper standards and government regulations for digital health solutions, which offer huge potential to providers who cannot meet stringent standards set by the federal government in the US. The patient-doctor ratio in these regions is also significantly high, necessitating alternative healthcare solutions.

These countries have also registered widespread adoption of smartphones and related technologies due to their growing affordability. Globally, China and India are the top two countries in terms of smartphone ownership. Furthermore, the increasing access to smart devices and the Internet has encouraged the development of health apps. In addition, government bodies in these regions are taking initiatives to improve HCIT infrastructure. For instance, in its five-year plan from 2015 to 2020, China aimed to improve healthcare quality by implementing HCIT solutions.

Challenges: Reluctance among patients to adopt digital therapeutics

Motivating people to use digital therapeutics and building their confidence is a major challenge faced by digital therapeutics providers. While older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, the limit of how much behavioral change will be observed with digital therapeutics is still undefined.

The clinical validation and deployment of digital therapeutics are carried out on self-selected or volunteer patients; however, their effect on patients showing resistance is still unknown. Furthermore, it is unknown whether digital therapeutics can be sustained over longer periods; there is little information on total patient retention and long-term outcomes. Many patients still rely on traditional means of diagnosis and treatment and thus show reluctance to adopt these novel therapies. This poses a major challenge to the digital therapeutics market.

Based on Sales, the B2B segment is expected to account for the largest share of the Digital Therapeutics Market, by Sales in 2021

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products

Based on applications, Treatment/Care related Applications are the largest share of the Digital Therapeutics Market, by applications in 2021

Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The largest share is the treatment/care related applications. This segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

North America to dominate the Digital Therapeutics Market market

The digital therapeutics market is segmented into North America, Europe, the Asia Pacific, and the RoW. In 2020, North America held the largest share of the market, followed by Europe. The market in North America is also expected to grow at the highest CAGR. Factors such as the influx of new startups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Digital Therapeutics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Prominent players in the digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), CogniFit (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).

Scope of the Report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD Billion)

Segments Covered

Sales Channel, Application, and Region

Geographies Covered

North America (US and Canada), Europe (Germany, UK, France, Spain, Italy, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and the Rest of the World

Companies Covered

Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), Ginger (US) BehaVR (US), Mindable Health (Germany), Virta Health (US), Hinge Health (US), and Doktor.se (Sweden)

The research report categorizes the digital therapeutics market into the following segments and subsegments:

Digital Therapeutics Market, by Sales Channel

  • B2C
    • Patients
    • Caregivers
  • B2B
    • Providers
    • Payers
    • Employers
    • Pharmaceutical Companies
    • Other Buyers

Digital Therapeutics Market, by Application

  • Preventive Applications
    • Prediabetes
    • Obesity
    • Nutrition
    • Lifestyle Management
    • Other Preventive Applications
  • Treatment/Care-related Applications
    • Diabetes
    • CNS Disorders
      • Mental Health Disorder
      • Other CNS Disorders
    • Chronic Respiratory Disorders
    • Musculoskeletal Disorders
    • Cardiovascular Diseases
    • Smoking Cessation
    • Medication Adherence
    • Gastrointestinal Disorders
    • Substance Use & Addiction Management
    • Rehabilitation & Patient Care
    • Other Treatment/Care-related Applications

Digital Therapeutics Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe (RoE)
  • APAC
    • Japan
    • China
    • India
    • Rest of the APAC
  • Rest of the World (RoW)

Recent Developments:

  • In April 2021, Welldoc(US) partnered with Dexacom (US). This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.
  • In March 2021, Pear Therapeutics (US) partnered with Sprectrum Health Systems (US). Tufts Health Plan and Spectrum Health Systems announced a collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation
  • In January 2020, Crossroads Treatment Centers (US) collaborated with Pear Therapeutics (US) to implement the company’s digital platform reSET-O to help patients with opioid abuse and addiction.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 LIMITATIONS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                                FIGURE 3 KEY INDUSTRY INSIGHTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach one: revenue mapping-based estimation
                                FIGURE 6 ESTIMATION OF THE DIGITAL THERAPEUTICS MARKET: REVENUE MAPPING-BASED ESTIMATION
                    2.2.1.2 Approach two: Buyer adoption-based estimation
                                FIGURE 7 MARKET SIZE ESTIMATION: BUYER ADOPTION-BASED
           2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION
                    FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION
           2.2.3 GROWTH FORECAST
                     TABLE 1 FACTOR ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET PLAYER RANKING
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 10 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL: PAYERS HOLD THE LARGEST MARKET SHARE
    FIGURE 13 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2021–2026)
    FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL THERAPEUTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
           FIGURE 16 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS ARE DRIVING THE ADOPTION OF DIGITAL THERAPEUTICS
    4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026
           FIGURE 17 B2B SALES DOMINATE THE DIGITAL THERAPEUTICS MARKET
    4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR DIGITAL THERAPEUTICS

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of preventable chronic diseases
                    5.2.1.2 Rising focus on preventive healthcare
                    5.2.1.3 Need to control healthcare costs
                    5.2.1.4 Significant increase in venture capital investments
                    5.2.1.5 Benefits of digital therapeutics
                               5.2.1.5.1 Ability to induce behavioral change
                               5.2.1.5.2 Improved drug adherence
                               5.2.1.5.3 Patient convenience and user-friendliness
           5.2.2 RESTRAINTS
                    5.2.2.1 Patient data privacy concerns
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Large undiagnosed and untreated population
                    5.2.3.3 Unexplored therapeutic applications
           5.2.4 CHALLENGES
                    5.2.4.1 Unstable payment models
                    5.2.4.2 Reluctance among patients to adopt digital therapeutics
                    5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries
                    5.2.4.4 Resistance from traditional healthcare providers
    5.3 PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 BARGAINING POWER OF SUPPLIERS
           5.3.3 BARGAINING POWER OF BUYERS
           5.3.4 THREAT OF SUBSTITUTES
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 VALUE CHAIN ANALYSIS
           FIGURE 20 VALUE CHAIN ANALYSIS
    5.5 ECOSYSTEM ANALYSIS
           FIGURE 21 ECOSYSTEM ANALYSIS
    5.6 PIPELINE PRODUCTS
    5.7 TECHNOLOGY TRENDS
    5.8 CASE STUDIES
    5.9 REGULATORY LANDSCAPE
           TABLE 2 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES
    5.10 IMPACT OF COVID-19 ON THE DIGITAL THERAPEUTICS MARKET

6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (Page No. - 68)
    6.1 INTRODUCTION
           TABLE 3 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    6.2 TREATMENT/CARE-RELATED APPLICATIONS
           TABLE 4 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 5 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           6.2.1 DIABETES
                    6.2.1.1 Rising prevalence of diabetes to drive market growth
                                TABLE 6 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2019–2026 (USD MILLION)
           6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
                    TABLE 7 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 8 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    6.2.2.1 Mental health disorders
                               6.2.2.1.1 Potential benefits of digital therapeutics in mental health disorder management have driven the development of these solutions
                                             TABLE 9 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    6.2.2.2 Other CNS disorders
                                TABLE 10 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2019–2026 (USD MILLION)
           6.2.3 SMOKING CESSATION
                    6.2.3.1 Focus on providing clinically validated, effective mobile applications to help quit smoking to aid market growth
                                TABLE 11 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2019–2026 (USD MILLION)
           6.2.4 CHRONIC RESPIRATORY DISEASES
                    6.2.4.1 Growing prevalence of COPD and asthma to drive market growth
                                TABLE 12 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2019–2026 (USD MILLION)
           6.2.5 MUSCULOSKELETAL DISORDERS
                    6.2.5.1 Dearth of physiotherapists to support market growth
                                TABLE 13 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)
           6.2.6 CARDIOVASCULAR DISEASE
                    6.2.6.1 High burden of CVD across the globe is the major factor driving the demand for digital therapeutics solutions
                                TABLE 14 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2019–2026 (USD MILLION)
           6.2.7 MEDICATION ADHERENCE
                    6.2.7.1 Growing number of medication non-adherence cases to propel market growth
                                TABLE 15 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2019–2026 (USD MILLION)
           6.2.8 GASTROINTESTINAL DISORDERS
                    6.2.8.1 High prevalence of gastrointestinal disorders has attracted many startups in the space of digital health
                                TABLE 16 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)
           6.2.9 REHABILITATION & PATIENT CARE
                    6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care
                                TABLE 17 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2019–2026 (USD MILLION)
           6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
                    6.2.10.1 Potential to improve the efficiency of behavioral interventions to drive market growth
                                TABLE 18 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2019–2026 (USD MILLION)
           6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
                     TABLE 19 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
    6.3 PREVENTIVE APPLICATIONS
           TABLE 20 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 21 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 PREDIABETES
                    6.3.1.1 Influx of startups to provide effective prevention against prediabetes will support market growth
                                TABLE 22 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2019–2026 (USD MILLION)
           6.3.2 OBESITY
                    6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth
                                TABLE 23 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2019–2026 (USD MILLION)
           6.3.3 NUTRITION
                    6.3.3.1 Importance of nutrition in preventing a wide range of ailments has driven the demand for digital therapeutic solutions
                                TABLE 24 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2019–2026 (USD MILLION)
           6.3.4 LIFESTYLE MANAGEMENT
                    6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes has contributed to the rising demand
                                TABLE 25 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2019–2026 (USD MILLION)
           6.3.5 OTHER PREVENTIVE APPLICATIONS
                    TABLE 26 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL (Page No. - 87)
    7.1 INTRODUCTION
           TABLE 27 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
    7.2 B2B
           TABLE 28 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 29 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2019–2026 (USD MILLION)
           7.2.1 PAYERS
                    7.2.1.1 Payers held the largest market share
                                TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 EMPLOYERS
                    7.2.2.1 Importance of employee health management has increased the adoption of digital therapeutics among employers
                                TABLE 31 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2019–2026 (USD MILLION)
           7.2.3 PHARMACEUTICAL COMPANIES
                    7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth
                                TABLE 32 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION)
           7.2.4 PROVIDERS
                    7.2.4.1 Potential for better patient management and cost-reductions are driving the demand for digital therapeutics among providers
                                TABLE 33 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2019–2026 (USD MILLION)
           7.2.5 OTHER BUYERS
                    TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2019–2026 (USD MILLION)
    7.3 B2C
           TABLE 35 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2019–2026 (USD MILLION)
           7.3.1 CAREGIVERS
                    7.3.1.1 Ease of managing health conditions has driven the demand for solutions among caregivers
                                TABLE 37 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2019–2026 (USD MILLION)
           7.3.2 PATIENTS
                    7.3.2.1 Awareness about preventive health among patients to support the growth of this segment
                                TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2019–2026 (USD MILLION)

8 DIGITAL THERAPEUTICS MARKET, BY REGION (Page No. - 97)
    8.1 INTRODUCTION
           TABLE 39 DIGITAL THERAPEUTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.2 NORTH AMERICA
           FIGURE 22 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT
           TABLE 40 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 41 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 42 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 43 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 44 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 45 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
           TABLE 46 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 47 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.2.1 US
                    8.2.1.1 Major digital therapeutics start-ups are based out of the US, which has greatly supported access to solutions
                                TABLE 48 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 49 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 50 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 51 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 52 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 53 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 54 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada
                                TABLE 55 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 56 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 57 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 58 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 59 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 60 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 61 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
    8.3 EUROPE
           FIGURE 23 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT
           TABLE 62 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 63 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 64 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 65 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 66 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 67 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
           TABLE 68 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 69 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.1 GERMANY
                    8.3.1.1 Germany is the largest market for digital therapeutics market in Europe due to increasing government initiatives
                                TABLE 70 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 71 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 72 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 73 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 74 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 75 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 76 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.2 UK
                    8.3.2.1 Well-established healthcare system and government support will propel the growth of the market
                                TABLE 77 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 78 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 79 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 80 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 81 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 82 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 83 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market growth in France
                                TABLE 84 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 85 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 86 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 87 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 88 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 89 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 90 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.4 SPAIN
                    8.3.4.1 Initiatives by emerging digital therapeutics startups are supporting market growth
                                TABLE 91 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 92 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 93 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 94 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 95 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 96 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 97 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.5 ITALY
                    8.3.5.1 Need for alternative and effective treatment to drive the market growth in the coming years
                                TABLE 98 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 99 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 100 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 101 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 102 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,2019–2026 (USD MILLION)
                                TABLE 103 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 104 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.3.6 REST OF EUROPE
                    TABLE 105 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                    TABLE 106 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 107 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 108 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 109 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                    TABLE 110 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                    TABLE 111 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
    8.4 ASIA PACIFIC
           TABLE 112 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 113 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 114 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 115 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 116 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
           TABLE 118 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 119 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.4.1 JAPAN
                    8.4.1.1 Rising diabetes incidence and collaborations between stakeholders are indicators of market growth in Japan
                                TABLE 120 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 121 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 122 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 123 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 124 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 125 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 126 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.4.2 CHINA
                    8.4.2.1 The growing geriatric population and incidence of chronic conditions will drive demand for digital therapeutics in China
                                TABLE 127 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 128 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 129 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 130 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 131 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 132 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 133 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.4.3 INDIA
                    8.4.3.1 Rising chronic disease incidence and the need for better disease management drive market growth
                                TABLE 134 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                TABLE 135 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 136 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 137 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 138 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                                TABLE 139 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                                TABLE 140 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           8.4.4 REST OF APAC
                    TABLE 141 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                    TABLE 142 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 143 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 144 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 145 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
                    TABLE 146 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
                    TABLE 147 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
    8.5 REST OF THE WORLD
           TABLE 148 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 149 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 150 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 151 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 152 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION)
           TABLE 153 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)
           TABLE 154 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 153)
    9.1 OVERVIEW
           FIGURE 24 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2016 AND 2021
    9.2 MARKET RANKING ANALYSIS, 2021
           FIGURE 25 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2021
    9.3 COMPANY EVALUATION MATRIX
           9.3.1 INTRODUCTION
           9.3.2 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY
                    9.3.2.1 Stars
                    9.3.2.2 Emerging leaders
                    9.3.2.3 Pervasive players
                    9.3.2.4 Emerging companies
                                FIGURE 26 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2021
           9.3.3 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2021)
                    9.3.3.1 Progressive companies
                    9.3.3.2 Starting blocks
                    9.3.3.3 Responsive companies
                    9.3.3.4 Dynamic companies
                                FIGURE 27 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
    9.4 COMPETITIVE SCENARIO
           9.4.1 DEALS
                    TABLE 155 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2016 TO JUNE 2021
           9.4.2 PRODUCT LAUNCHES
                    TABLE 156 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES, JANUARY 2016 TO JUNE 2021
           9.4.3 EXPANSIONS
                    TABLE 157 DIGITAL THERAPEUTICS MARKET: EXPANSIONS, JANUARY 2016 TO JUNE 2021

10 COMPANY PROFILES (Page No. - 163)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     10.1 NOOM, INC.
     10.2 LIVONGO HEALTH
     10.3 OMADA HEALTH
     10.4 COGNIFIT
     10.5 WELLDOC
     10.6 GINGER
     10.7 PROPELLER HEALTH
     10.8 2MORROW, INC.
     10.9 CANARY HEALTH
     10.10 MANGO HEALTH, INC.
     10.11 CLICK THERAPEUTICS
     10.12 PEAR THERAPEUTICS
     10.13 AKILI INTERACTIVE LABS, INC.
     10.14 WELLTHY THERAPEUTICS
     10.15 COGNOA, INC.
     10.16 HAPPIFY
     10.17 KAIA HEALTH
     10.18 AYOGO HEALTH
     10.19 BETTER THERAPEUTICS
     10.20 MINDSTRONG HEALTH
     10.21 BEHAVR INC.
     10.22 MINDABLE HEALTH
     10.23 VIRTA HEALTH
     10.24 HINGE HEALTH
     10.25 DOKTOR.SE

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 197)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS

The study involved four major activities in estimating the current size of the global digital therapeutics market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the digital therapeutics market. Secondary sources include directories; databases such as Bloomberg Businessweek, Factiva, and Wall Street Journal; white papers; and annual reports that were used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of primary respondents:

Digital Therapeutics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the digital therapeutics market. These methods were also used extensively to determine the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The research methodology included the study of annual and quarterly financial reports and regulatory filings, data books of major market players, as well as interviews with industry experts for detailed market insights.
  • All percentage shares, splits, and breakdowns for the global digital therapeutics market were determined by using secondary sources and verified through primary sources
  • All key macro indicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data
  • The gathered market data was consolidated and added with detailed inputs and analysis, and presented in this report

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the digital therapeutics market based on sales channel, application, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall digital therapeutics market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)2
  • To profile key players and analyze their market shares and core competencies3
  • To track and analyze competitive developments such as product launches, partnerships, agreements, expansions, mergers, and acquisitions in the digital therapeutics market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Digital Therapeutics (DTx) Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Digital Therapeutics (DTx) Market

Request For Special Pricing
Report Code
HIT 4407
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Digital Therapeutics (DTx) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved